AttendMe Owl Logo
AttendMe
Evidence Evolution
EndocrinologyEndocrinology

How This Evidence Evolved

Adrenal Incidentaloma Approach

From incidental finding to evidence-based risk stratification

7.4

Timeline

Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

Adrenal incidentalomas are asymptomatic adrenal masses found on imaging done for other reasons, and their prevalence was expected to keep rising. In 2002, an NIH state-of-the-science panel noted that the low prevalence of adrenocortical carcinoma and the low rate of progression to hyperfunction called into question the practice of intense, long-term follow-up. It advised a 1-mg dexamethasone suppression test and plasma-free metanephrines for all patients, plus serum potassium and an aldosterone/renin ratio in hypertension; tumors >6 cm were usually treated surgically and tumors <4 cm generally monitored.
Proof

Landmark RCTs and pivotal trials that established the evidence base

The 2016 ESE/ENSAT guideline provided evidence-based recommendations for adrenal incidentaloma management. It addressed malignancy risk, autonomous cortisol secretion, surgical selection and follow-up. It recommended a 1 mg overnight dexamethasone suppression test, using a post-test cortisol cutoff of 50 nmol/L to exclude autonomous cortisol secretion.
Extension

Follow-up studies, subgroup analyses, and real-world validation

The 2023 ESE/ENSAT guideline states that homogeneous lesions with HU ≤10 on unenhanced CT are benign and need no further imaging, independent of size. In patients without overt Cushing’s syndrome, post-dexamethasone cortisol >50 nmol/L is termed mild autonomous cortisol secretion (MACS). Recent studies linked this finding to increased morbidity and mortality. The guideline calls for clinical and endocrine assessment to exclude hormone excess and individualized decisions when MACS coexists with relevant comorbidities.
Guidelines

Integration into clinical practice guidelines and recommendations

ESE/ENSAT
Now

Current standard of care and ongoing research directions

Adrenal incidentaloma management balances assessment of malignancy and hormone excess against unnecessary investigation. The 2023 ESE/ENSAT guideline recommends no additional imaging for homogeneous lesions with HU ≤10, independent of size. Post-dexamethasone cortisol >50 nmol/L without overt Cushing’s syndrome is termed MACS and is associated with increased morbidity and mortality. The guideline calls for individualized consideration of surgery when MACS coexists with relevant comorbidities; optimal selection for surgery versus monitoring remains a clinical question.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What workup is needed for an adrenal incidentaloma?+
Per ESE/ENSAT 2023 guidelines: (1) dedicated adrenal imaging; homogeneous lesions with HU ≤10 on unenhanced CT are benign and need no further imaging; (2) 1 mg overnight dexamethasone suppression test (cutoff ≤50 nmol/L); (3) plasma or urinary metanephrines in every patient; The earlier NIH panel advised an aldosterone-renin ratio if hypertensive. Surgery is usually the choice only for lesions >4 cm that are inhomogeneous or have HU >20; otherwise it is guided by malignancy likelihood, hormone excess, age, general health and patient preference.
How often does an adrenal incidentaloma require follow-up?+
Under the 2023 ESE/ENSAT guidelines, homogeneous lesions with HU ≤10 on unenhanced CT are benign and do not require any additional imaging, independent of size. All other patients should be discussed in a multidisciplinary expert meeting.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026